Search results
Added:
8 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more
Added:
1 month ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 month ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Added:
2 years ago
AHA 2023 — In this short interview, we are joined by Dr John Hummel (Ohio State University, US) to discuss the findings from the JEWEL-IDE (NCT05201495) study, which investigated the use of the Jewel patch-wearable cardioverter defibrillator (PWCD) system in participants who were at high risk for sudden cardiac arrest. This was a multicenter, prospective, single-arm trial, with 290 participants…
View more
Added:
1 month ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Added:
3 months ago
Added:
2 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
3 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more
Start date:
Jul 02, 2025
.img-row:after {
content: "";
clear: both;
display: table;
}
.img-column {
float: left;
width: 50%;
padding: 5px;
}
@media screen and (max-width: 500px) {
.img-column {
width: 100%;
}
}
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)…
View more
Added:
3 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more